http://web.archive.org/web/20140801204107id_/http://www.dailymail.co.uk/news/article-2547125/Thousands-prostate-patients-denied-drug-extend-life-five-months-watchdog-U-turn.html

by @entity0 thousands of men with advanced prostate cancer could be denied a new drug after a u-turn by the @entity6 rationing body thousands of men with advanced prostate cancer could be denied a new drug after a u-turn by the @entity6 rationing body			1
@entity9 extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months			1
it was initially recommended for @entity6 funding last october but revised draft guidance issued today imposes curbs that will deny many men the chance to use it			1
it will be banned for patients in @entity22 previously treated with abiraterone , another new drug currently used in advanced cases			1
men in @entity27 are getting enzalutamide without restrictions			2
rationing watchdog the @entity30 ( @entity30 ) says lack of evidence about the two drugs has led to its revised decision , which is now out for consultation			2
cancer specialists are outraged , saying it is a perverse u-turn based on fears about the cost			0
around 10,500 @entity42 men have advanced prostate cancer that is resistant to standard hormone treatments			1
doctors say enzalutamide could help turn prostate cancer from a killer disease into a chronic illness			1
dr @entity50 , consultant oncologist at the @entity51 , @entity52 , described the ruling as a tragedy			0
‘ thousands of men have been prescribed abiraterone or are using it in trials , and they will be denied this new drug at some point , ’ she said			2
‘ new drugs have shown that advanced prostate cancer can be turned into a chronic disease , with men having good quality of life for months or even years			1
they are able to work and reach the milestones in life that matter to them			0
‘ i ’m outraged by this perverse decision			0
this would not happen in breast cancer			0
’ @entity9 , a new type of hormone treatment , was assessed in 1,199 patients with advanced prostate cancer who had previously received chemotherapy			1
their survival rates were significantly extended , with almost half having a better quality of life as a result			0
around 10,500 @entity42 men have advanced prostate cancer that is resistant to standard hormone treatments @entity9 , which is a pill taken at home , costs around £ 25,000 for an average course of treatment			1
but manufacturer @entity88 has reduced the price through a patient scheme that makes it cost - effective , according to @entity30			0
@entity91 , chief executive at the charity @entity93 @entity42 , criticised @entity30			2
‘ adding this restriction to their draft decision , without any explanation , leaves hundreds of men , who have few treatments anyway , with no hope of accessing enzalutamide , ’ he said			2
‘ @entity30 is playing fast and loose with men with prostate cancer in the advanced stages of the disease who may become resistant to other treatments , and what ’s worse , without saying why			1
‘ we will fight this decision , but it will not help the men who could be benefiting during this delay			0
we hope @entity30 follow the decision made in @entity27 , and allow clinicians to make the decisions about what drugs are best for patients			0
’ professor @entity118 , a leading prostate cancer specialist , said @entity30 was an organisation ‘ not fit for purpose ’ that persists in using a faulty system for rationing drugs that disadvantages patients in @entity22			1
‘ it continues to evaluate drugs using calculations that do not reflect reality and exaggerate the cost , ’ he said			0
‘ these nonsensical decisions are made on behalf of patients but conflict with what specialists consider is best for them			0
’ he accused @entity30 of creating a postcode lottery			0
‘ this iniquitous guidance means men in @entity22 will be treated differently from @entity27 , ’ said professor @entity118			2
professor @entity140 , director of @entity30 ’s @entity141 , said : ‘ there are few treatments available for patients at this stage of prostate cancer so we are very pleased that we are able to produce draft guidance recommending enzalutamide			1

10,500 @entity42 men have advanced treatment resistant prostate cancer
new drug @entity9 can extend life by more than 18 months
it was initially recommended for @entity6 funding last october
revised draft guidance imposes curbs denying many men chance to use it

@entity22:England
@entity30:Nice
@entity0:Jenny Hope
@entity140:Carole Longson
@entity6:NHS
@entity9:Enzalutamide
@entity27:Scotland
@entity52:Royal Preston Hospital
@entity51:Rosemere Cancer Centre
@entity50:Alison Birtle
@entity42:British
@entity88:Astellas Pharma
@entity118:Waxman
@entity93:Prostate Cancer
@entity91:Owen Sharp
@entity141:Centre for Health Technology Evaluation